Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial
Blood · 2025
DOI: 10.1182/blood.2024027342 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Blood, 2025. Verfasst von Marc-Andrea Baertsch und 26 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg Myeloma Center and GMMG Study Group, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, …. Hauptthemen laut MEDLINE: Multiple Myeloma, Salvage Therapy, Hematopoietic Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The multicenter, phase 3 German-Speaking Myeloma Multicenter Group (GMMG) ReLApsE trial randomized patients with relapsed and/or refractory multiple myeloma (RRMM) equally to lenalidomide/dexamethasone (LEN/DEX; 25 mg days 1-21, DEX 40 mg weekly, in 4-week cycles) reinduction, salvage high-dose chemotherapy (sHDCT; melphalan 200 mg/m2), autologous stem cell transplantation (ASCT), and LEN maintenance (10 mg/d; transplant arm, n = 139) vs continuous LEN/DEX (control arm, n = 138). Ninety-four percent of patients had received frontline HDCT/ASCT. We report an updated analysis of survival end points with a median follow-up of 99 months. Median progression-free survival (PFS) was 20.5 and 19.3 months in the transplant and control arm, respectively (hazard ratio [HR], 0.98; P = .9). Median overall survival (OS) was 67.1 and 62.7 months, respectively, (HR 0.89; P = .44). Landmark analyses from sHDCT and the contemporaneous LEN/DEX cycle 5 were performed because of 29% dropout of patients before sHDCT/ASCT in the transplant arm but did not reveal significant differences in PFS/OS. Time to progression after frontline HDCT/ASCT was a prognostic factor but did not predict benefit from sHDCT/ASCT. The GMMG ReLApsE trial does not support use of sHDCT/ASCT in RRMM after frontline HDCT/ASCT. This trial was registered at www.clinicaltrialsregister.eu as #EudraCT2009-013856-61.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Heidelberg Myeloma Center and GMMG Study Group, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.
- Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany.
- Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
- National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Hematology, Cell Therapy, Hemostaseology and Infectiology, Leipzig University Hospital, Leipzig, Germany.
- Coordination Centre for Clinical Trials, University Hospital Heidelberg, Heidelberg, Germany.
ORCID-Profile: Marc-Andrea Baertsch, Marc S Raab, Maximilian Merz, Elias Karl Mai, Carsten Müller-Tidow, Stefan Klein, Hans W Lindemann, Christof Scheid, Hartmut Goldschmidt
Zitieren
APA
Baertsch, M. A., Schlenzka, J., Hielscher, T., Raab, M. S., Sauer, S., Merz, M., Mai, E. K., Müller-Tidow, C., Luntz, S., Jauch, A., Brossart, P., Goerner, M., Klein, S., Glass, B., Reimer, P., Graeven, U., Fenk, R., Haenel, M., von Metzler, I., …, & Goldschmidt, H. (2025). Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial. Blood. https://doi.org/10.1182/blood.2024027342
Vancouver
Baertsch MA, Schlenzka J, Hielscher T, Raab MS, Sauer S, Merz M, et al. Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial. Blood. 2025. doi:10.1182/blood.2024027342
BibTeX
@article{Baertsch2025,
author = {Baertsch, Marc-Andrea and Schlenzka, Jana and Hielscher, Thomas and Raab, Marc S and Sauer, Sandra and Merz, Maximilian and Mai, Elias Karl and Müller-Tidow, Carsten and Luntz, Steffen and Jauch, Anna and Brossart, Peter and Goerner, Martin and Klein, Stefan and Glass, Bertram and Reimer, Peter and Graeven, Ullrich and Fenk, Roland and Haenel, Mathias and von Metzler, Ivana and Lindemann, Hans W and Scheid, Christof and Blau, Igor-Wolfgang and Salwender, Hans J and Noppeney, Richard and Besemer, Britta and Weisel, Katja C and Goldschmidt, Hartmut},
title = {Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial},
journal = {Blood},
year = {2025},
doi = {10.1182/blood.2024027342}
}
EUVIMED